| 1. |
- Niemi, MEK, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 2. |
- Kanai, M, et al.
(författare)
-
- 2023
-
swepub:Mat__t
|
|
| 3. |
|
|
| 4. |
- Home, P.D., et al.
(författare)
-
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
- 2009
-
Ingår i: The Lancet. - : Elsevier: Lancet. - 0140-6736 .- 1474-547X. ; 373:9681, s. 2125-2135
-
Tidskriftsartikel (refereegranskat)abstract
- Background: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We assessed cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea compared with the combination of the two over 5-7 years of follow-up. We also assessed comparative safety. Methods: In a multicentre, open-label trial, 4447 patients with type 2 diabetes on metformin or sulfonylurea monotherapy with mean haemoglobin A 1c (HbA 1c) of 7·9% were randomly assigned to addition of rosiglitazone (n=2220) or to a combination of metformin and sulfonylurea (active control group, n=2227). The primary endpoint was cardiovascular hospitalisation or cardiovascular death, with a hazard ratio (HR) non-inferiority margin of 1·20. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00379769. Findings: 321 people in the rosiglitazone group and 323 in the active control group experienced the primary outcome during a mean 5·5-year follow-up, meeting the criterion of non-inferiority (HR 0·99, 95% CI 0·85-1·16). HR was 0·84 (0·59-1·18) for cardiovascular death, 1·14 (0·80-1·63) for myocardial infarction, and 0·72 (0·49-1·06) for stroke. Heart failure causing admission to hospital or death occurred in 61 people in the rosiglitazone group and 29 in the active control group (HR 2·10, 1·35-3·27, risk difference per 1000 person-years 2·6, 1·1-4·1). Upper and distal lower limb fracture rates were increased mainly in women randomly assigned to rosiglitazone. Mean HbA 1c was lower in the rosiglitazone group than in the control group at 5 years. Interpretation: Addition of rosiglitazone to glucose-lowering therapy in people with type 2 diabetes is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Although the data are inconclusive about any possible effect on myocardial infarction, rosiglitazone does not increase the risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs. Funding: GlaxoSmithKline plc, UK. © 2009 Elsevier Ltd. All rights reserved.
|
|
| 5. |
|
|
| 6. |
- Otieno, Austine O., et al.
(författare)
-
Pineapple peel biochar and lateritic soil as adsorbents for recovery of ammonium nitrogen from human urine
- 2021
-
Ingår i: Journal of Environmental Management. - : Elsevier. - 0301-4797 .- 1095-8630. ; 293
-
Tidskriftsartikel (refereegranskat)abstract
- Human urine is a rich source of nitrogen which can be captured to supplement the existing sources of nitrogen fertilizers thus contributing to enhanced crop production. However, urine is the major contributor of macronutrients in municipal wastewater flows resulting into eutrophication of the receiving water bodies. Herein, pineapple peel biochar (PPB), and lateritic soil (LS) adsorbents were prepared for the safe removal of ammonium nitrogen (NH4+-N) from human urine solutions. Physicochemical properties of PPB, and LS were characterized by scanning electron microscopy-energy dispersive spectroscopy (SEM-EDS), X-ray powder diffraction (XRD), Fourier transform infrared spectroscopy (FTIR) and thermogravimetric analysis (TGA) to investigate the relationship of their properties with NH4+-N adsorption. Langmuir, Freundlich, and Dubinin-Radushkevich (D-R) isotherm models were employed to correlate the experimental equilibrium adsorption data. The effect of contact time and initial concentration of NH4+-N adsorption was also evaluated. The D-R isotherm model best described the behaviour of NH4+-N adsorption on both PPB and LS based on the coefficient of correlation values. This model showed that the adsorption of NH4+-N on both samples was a physical process with PPB and LS having mean surface adsorption energies of 1.826 × 10−2, and 1.622 × 10−2 kJ/mol, respectively. The PPB exhibited a slightly higher adsorption capacity for NH4+-N (13.40 mg/g) than LS (10.73 mg/g) with the difference attributed to its higher surface area and porosity. These values are good indicators for assessing the effectiveness of the materials for adsorption of NH4+-N from human urine.
|
|
